Shares of Halozyme (HALO) spiked in afternoon trading june 28 after its partner Roche Holding AG (RHHBY) received a positive recommendation from a European advisory committee on its injectable form of Herceptin, a breast cancer drug.
According to Halozyme CEO Gregory Frost, a Phase 3 study on Herceptin indicated that the drug “may help decrease the time patients spend receiving treatment at a hospital or physician’s practice, by reducing the administration time.” Halozyme produces an enzyme for Herceptin that now allows it to be injected subcutaneously.
A typical IV infusion of Herceptin takes 30-90 minutes, but Herceptin can now be administered in just two to five minutes via injection under the skin. Roche is currently seeking European approval for the injectable drug, so the recommendation is a very encouraging sign.
“Pending European approval, this subcutaneous formulation of Herceptin will provide a new route of administration that could potentially save time for both physicians and HER2-positive breast cancer patients in Europe,” Frost said. The breakthrough could be a complete game changer in the breast cancer drug space, as treatments are usually time consuming for both patients and doctors.
Halozyme shares spiked during trading hours on June 28 when the news was released. The stock reached a daily high of $8.20, a gain of around 30 percent since close on June 27.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer